ArticleThe Journal of clinical investigation2000
Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion.
Article in The Journal of clinical investigation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 81 citations in OpenAlex.
- Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo.Clinical and experimental hypertension (New York, N.Y. : 1993) · 2010Trial
- Psychophysiological effects of a web-based stress management system: a prospective, randomized controlled intervention study of IT and media workers [ISRCTN54254861].BMC public health · 2005Trial
- Endometriosis Is Associated with Increased Serum and Peritoneal Fluid Concentrations of Chromogranin A and Its Derivatives.Journal of clinical medicine · 2026Article
- Inflammation Promotes Proteolytic Processing of the Prohormone Chromogranin A by Macrophages.Journal of the Endocrine Society · 2025Article
- A complex role of chromogranin A and its peptides in inflammation, autoimmunity, and infections.Frontiers in immunology · 2025Review
- Thrombolysis exacerbates cerebrovascular injury after ischemic stroke via a VEGF-B dependent effect on adipose lipolysis.bioRxiv : the preprint server for biology · 2024Article
- Catestatin: Antimicrobial Functions and Potential Therapeutics.Pharmaceutics · 2023Review
- Review
- Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality.Frontiers in immunology · 2022Article
- Putative regulation of macrophage-mediated inflammation by catestatin.Trends in immunology · 2022Review
- Functions of the plasminogen receptor Plg-RJournal of thrombosis and haemostasis : JTH · 2020Review
- Article
- Neuroendocrine Targeting of Tissue Plasminogen Activator (t-PA).Journal of neurological disorders & stroke · 2020Article
- Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation.Annals of the New York Academy of Sciences · 2019Review
- Review
- The plasminogen receptorJournal of thrombosis and haemostasis : JTH · 2018Article
- Slow fusion pore expansion creates a unique reaction chamber for co-packaged cargo.The Journal of general physiology · 2017Article
- Deficiency of plasminogen receptor, Plg-RJournal of thrombosis and haemostasis : JTH · 2017Article
- Article
- Lumenal protein within secretory granules affects fusion pore expansion.Biophysical journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Chromogranin A (CgA) is the major soluble protein in the core of catecholamine-storage vesicles and is also distributed widely in secretory vesicles throughout the neuroendocrine system. CgA contains the sequences for peptides that modulate catecholamine release, but the proteases responsible for the release of these bioactive peptides from CgA have not been established. We show here that the major fibrinolytic enzyme, plasmin, can cleave CgA to form a series of large fragments as well as small trichloroacetic acid-soluble peptides. Peptides generated by plasmin-mediated cleavage of CgA significantly inhibited nicotinic cholinergic stimulation of catecholamine release from PC12 cells and primary bovine adrenal chromaffin cells. We also show that the zymogen, plasminogen, as well as tissue plasminogen activator bind saturably and with high capacity to catecholaminergic (PC12) cells. Occupancy of cell surface binding sites promoted the cleavage of CgA by plasmin. Positive and negative modulation of the local cellular fibrinolytic system resulted in substantial alterations in catecholamine release. These results suggest that catecholaminergic cells express binding sites that localize fibrinolytic molecules on their surfaces to promote plasminogen activation and proteolytic processing of CgA in the environment into which CgA is secreted to generate peptides which may regulate neuroendocrine secretion. Interactions between CgA and plasmin(ogen) define a previously unrecognized autocrine/paracrine system that may have a dramatic impact upon catecholamine secretion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.